Exploring satri-cel access in China for CLDN18.2 advanced gastric cancer? Learn what overseas patients should prepare before travel: records, pathology, imaging, hospital review, visa steps, and logistics.
MedBridgeNZ coordinates medical concierge support—not medical care.
Read guide: https://zurl.co/eVUUM
#MedicalTourismChina #SatriCel #CLDN182 #CARTCellTherapy

Satri-cel in China: CLDN18.2 Gastric Cancer Access Pathways
Home > Blog > Advanced Therapies & TechnologyKey Takeaways • The Chinese National Medical Products Administration (NMPA) approved satricabtagene autoleucel (satri-cel) as a cellular pathway for patients with Claudin18.2 (CLDN18.2) positive, HER2-negative advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma who have failed at least two prior systemic therapies. • Accessing this specialized pathway requires rigorous biomarker confirmation, including the translation and institutiona






